- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
- 40FR12B Initial registration of securities (Canada)
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 Exhibit 99.6
- 99.7 Exhibit 99.7
- 99.8 Exhibit 99.8
- 99.9 Exhibit 99.9
- 99.10 Exhibit 99.10
- 99.11 Exhibit 99.11
- 99.12 Exhibit 99.12
- 99.13 Exhibit 99.13
- 99.14 Exhibit 99.14
- 99.15 Exhibit 99.15
- 99.16 Exhibit 99.16
- 99.17 Exhibit 99.17
- 99.18 Exhibit 99.18
- 99.19 Exhibit 99.19
- 99.20 Exhibit 99.20
- 99.21 Exhibit 99.21
- 99.22 Exhibit 99.22
- 99.23 Exhibit 99.23
- 99.24 Exhibit 99.24
- 99.25 Exhibit 99.25
- 99.26 Exhibit 99.26
- 99.27 Exhibit 99.27
- 99.28 Exhibit 99.28
- 99.29 Exhibit 99.29
- 99.30 Exhibit 99.30
- 99.31 Exhibit 99.31
- 99.32 Exhibit 99.32
- 99.33 Exhibit 99.33
- 99.34 Exhibit 99.34
- 99.35 Exhibit 99.35
- 99.36 Exhibit 99.36
- 99.37 Exhibit 99.37
- 99.38 Exhibit 99.38
- 99.39 Exhibit 99.39
- 99.40 Exhibit 99.40
- 99.41 Exhibit 99.41
- 99.42 Exhibit 99.42
- 99.43 Exhibit 99.43
- 99.44 Exhibit 99.44
- 99.45 Exhibit 99.45
- 99.46 Exhibit 99.46
- 99.47 Exhibit 99.47
- 99.48 Exhibit 99.48
- 99.49 Exhibit 99.49
- 99.50 Exhibit 99.50
- 99.51 Exhibit 99.51
- 99.52 Exhibit 99.52
- 99.53 Exhibit 99.53
- 99.54 Exhibit 99.54
- 99.55 Exhibit 99.55
- 99.56 Exhibit 99.56
- 99.57 Exhibit 99.57
- 99.58 Exhibit 99.58
- 99.59 Exhibit 99.59
- 99.60 Exhibit 99.60
- 99.61 Exhibit 99.61
- 99.62 Exhibit 99.62
- 99.63 Exhibit 99.63
- 99.64 Exhibit 99.64
- 99.65 Exhibit 99.65
- 99.66 Exhibit 99.66
- 99.67 Exhibit 99.67
- 99.68 Exhibit 99.68
- 99.69 Exhibit 99.69
- 99.70 Exhibit 99.70
- 99.71 Exhibit 99.71
- 99.72 Exhibit 99.72
- 99.73 Exhibit 99.73
- 99.74 Exhibit 99.74
- 99.75 Exhibit 99.75
- 99.76 Exhibit 99.76
- 99.77 Exhibit 99.77
- 99.78 Exhibit 99.78
- 99.79 Exhibit 99.79
- 99.80 Exhibit 99.80
- 99.81 Exhibit 99.81
- 99.82 Exhibit 99.82
- 99.83 Exhibit 99.83
- 99.84 Exhibit 99.84
- 99.85 Exhibit 99.85
- 99.86 Exhibit 99.86
- 99.87 Exhibit 99.87
- 99.88 Exhibit 99.88
- 99.89 Exhibit 99.89
- 99.90 Exhibit 99.90
- 99.91 Exhibit 99.91
- 99.92 Exhibit 99.92
- 99.93 Exhibit 99.93
- 99.94 Exhibit 99.94
- 99.95 Exhibit 99.95
- 99.96 Exhibit 99.96
- 99.97 Exhibit 99.97
- 99.98 Exhibit 99.98
- 99.99 Exhibit 99.99
- 99.100 Exhibit 99.100
- 99.101 Exhibit 99.101
- 99.102 Exhibit 99.102
- 99.103 Exhibit 99.103
- 99.104 Exhibit 99.104
- 99.105 Exhibit 99.105
- 99.106 Exhibit 99.106
- 99.107 Exhibit 99.107
- 99.108 Exhibit 99.108
- 99.109 Exhibit 99.109
- 99.110 Exhibit 99.110
- 99.111 Exhibit 99.111
- 99.112 Exhibit 99.112
- 99.113 Exhibit 99.113
- 99.114 Exhibit 99.114
- 99.115 Exhibit 99.115
- 99.116 Exhibit 99.116
- 99.117 Exhibit 99.117
- 99.118 Exhibit 99.118
- 99.119 Exhibit 99.119
- 99.120 Exhibit 99.120
- 99.121 Exhibit 99.121
- 99.122 Exhibit 99.122
- 99.123 Exhibit 99.123
- 99.124 Exhibit 99.124
- 99.125 Exhibit 99.125
- 99.126 Exhibit 99.126
- 99.127 Exhibit 99.127
- 99.128 Exhibit 99.128
- 99.129 Exhibit 99.129
- 99.130 Exhibit 99.130
- 99.131 Exhibit 99.131
- 99.132 Exhibit 99.132
- 99.133 Exhibit 99.133
- 99.134 Exhibit 99.134
- 99.135 Exhibit 99.135
- 99.136 Exhibit 99.136
- 99.137 Exhibit 99.137
- 99.138 Exhibit 99.138
- 99.139 Exhibit 99.139
- 99.140 Exhibit 99.140
- 99.141 Exhibit 99.141
- 99.142 Exhibit 99.142
- 99.143 Exhibit 99.143
- 99.144 Exhibit 99.144
- 99.145 Exhibit 99.145
- 99.146 Exhibit 99.146
- 99.147 Exhibit 99.147
- 99.148 Exhibit 99.148
- 99.149 Exhibit 99.149
- 99.150 Exhibit 99.150
- 99.151 Exhibit 99.151
- 99.152 Exhibit 99.152
- 99.153 Exhibit 99.153
- 99.154 Exhibit 99.154
- 99.155 Exhibit 99.155
- 99.156 Exhibit 99.156
- 99.157 Exhibit 99.157
- 99.158 Exhibit 99.158
- 99.159 Exhibit 99.159
- 99.160 Exhibit 99.160
- 99.161 Exhibit 99.161
- 99.162 Exhibit 99.162
- 99.163 Exhibit 99.163
- 99.164 Exhibit 99.164
- 99.165 Exhibit 99.165
- 99.166 Exhibit 99.166
- 99.167 Exhibit 99.167
- 99.168 Exhibit 99.168
- 99.169 Exhibit 99.169
- 99.170 Exhibit 99.170
- 99.171 Exhibit 99.171
- 99.172 Exhibit 99.172
- 99.173 Exhibit 99.173
- 99.174 Exhibit 99.174
ZEN Graphene Solutions Provides COVID-19 Response Update
Thunder Bay, ON - June 08, 2020, ZEN Graphene Solutions Ltd. ("ZEN" or the "Company") (TSXV:ZEN) is pleased to report that it will be providing Albany PureTM Graphene Oxide produced by its Guelph facility for development of a rapid, ultrasensitive and low cost bio-sensor to detect the presence of the SARS-CoV-2 antigen and/or antibodies in COVID-19 suspected patients. This research is led by Prof. Maxim Berezovski, a full Professor at the University of Ottawa. Prof. Berezovski leads the Berezovski Research Group and the Bioanalytical and Molecular Interaction Laboratory. This research is funded by an initial grant of approximatively $400,000 from the National Sciences and Engineering Council (NSERC).
Francis Dubé, ZEN CEO commented, "It is an honour for ZEN to support the work of Prof. Berezovski and his international team in their quest for a novel diagnostic test of COVID-19. Graphene is a technology enabler and ZEN is focused on the innovations that graphene can bring including in biomedical applications and we welcome inquiries from all industries."
ZEN has also partnered with Prof. Aicheng Chen, Canada Research Chair Tier 1 in Electrochemistry and Nanoscience, who was awarded a $50,000 NSERC Alliance COVID-19 grant for a proposal titled "Development of Advanced Graphene-Based Antiviral Nanocomposites against COVID-19." ZEN will be providing an in-kind contribution of $26,700 in materials, staff salaries and access to its Guelph facility. This project builds directly on results and IP from previous NSERC CRD/OCE VIP II projects. ZEN looks forward to continuing its strong collaborative relationship with Prof. Chen and his team.
Additionally, ZEN continues development of a potential virucidal graphene oxide-based ink that could be applied to fabrics including N95 face masks and other personal protective equipment (PPE) for significantly increased protection. The Company has produced two batches of samples using different formulations now being tested by Western University's ImPaKT Facility Biosafety Level 3 lab for antiviral activity. ZEN has discontinued its collaboration with Graphene Composites Ltd. previously announced on April 30, 2020.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 virus at this time.
About ZEN Graphene Solutions Ltd.
ZEN is an emerging graphene technology solutions company with a focus on the development of graphene-based nanomaterial products and applications. The unique Albany Graphite Project provides the company with a potential competitive advantage in the graphene market as independent labs in Japan, UK, Israel, USA and Canada have independently demonstrated that ZEN's Albany PureTM Graphite is an ideal precursor material which easily converts (exfoliates) to graphene, using a variety of mechanical, chemical and electrochemical methods.
For further information:
Dr. Francis Dubé, Chief Executive Officer
Tel: +1 (289) 821-2820
Email: drfdube@zengraphene.com
To find out more about ZEN Graphene Solutions Ltd., please visit our website at www.ZENGraphene.com. A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at www.sedar.ca.
Forward-Looking Statements
This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although ZEN believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. ZEN disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.